Lymphatic Delivery with Pembrolizumab
Sector
MedTech
Company
Emerging MedTech
Therapeutic Area
Oncology
Treatment Modality
Drug-Device
Product Stage
Clinical
Expertise
Scientific Communications
An emerging medtech platform developed a proprietary microneedle fluidic system designed to deliver immuno-oncology therapies directly into the lymphatic system. Pembrolizumab, a PD-1 inhibitor with established efficacy across multiple tumor types, was selected as a model therapy to demonstrate the platform’s potential. The challenge was to communicate the scientific rationale and translational relevance of lymphatic delivery in a way that resonated with oncology stakeholders and distinguished the platform from conventional subcutaneous or intravenous administration.
Situation
An emerging medtech platform developed a proprietary microneedle fluidic system designed to deliver immuno-oncology therapies directly into the lymphatic system. Pembrolizumab, a PD-1 inhibitor with established efficacy across multiple tumor types, was selected as a model therapy to demonstrate the platform’s potential. The challenge was to communicate the scientific rationale and translational relevance of lymphatic delivery in a way that resonated with oncology stakeholders and distinguished the platform from conventional subcutaneous or intravenous administration.
Situation
Approach
Our work translated the mechanistic advantages of lymphatic targeting into a credible scientific narrative—showing how enhanced local immune activation could complement checkpoint inhibition. We developed congress content to highlight early pharmacokinetic and pharmacodynamic data, created briefing materials for KOL discussions, and supported publications that contextualized the technology against existing modes of pembrolizumab delivery. Communications emphasized rigor, comparability, and regulatory alignment, ensuring oncology audiences viewed the platform as both innovative and credible.
Our work translated the mechanistic advantages of lymphatic targeting into a credible scientific narrative—showing how enhanced local immune activation could complement checkpoint inhibition. We developed congress content to highlight early pharmacokinetic and pharmacodynamic data, created briefing materials for KOL discussions, and supported publications that contextualized the technology against existing modes of pembrolizumab delivery. Communications emphasized rigor, comparability, and regulatory alignment, ensuring oncology audiences viewed the platform as both innovative and credible.
Approach
Results
By reframing the device around its relevance to immuno-oncology, the company elevated visibility among oncology KOLs, strengthened confidence in the translational science, and positioned itself as a partner capable of extending the reach of checkpoint inhibitors through differentiated delivery.
By reframing the device around its relevance to immuno-oncology, the company elevated visibility among oncology KOLs, strengthened confidence in the translational science, and positioned itself as a partner capable of extending the reach of checkpoint inhibitors through differentiated delivery.
Situation
An emerging medtech platform developed a proprietary microneedle fluidic system designed to deliver immuno-oncology therapies directly into the lymphatic system. Pembrolizumab, a PD-1 inhibitor with established efficacy across multiple tumor types, was selected as a model therapy to demonstrate the platform’s potential. The challenge was to communicate the scientific rationale and translational relevance of lymphatic delivery in a way that resonated with oncology stakeholders and distinguished the platform from conventional subcutaneous or intravenous administration.
Approach
Our work translated the mechanistic advantages of lymphatic targeting into a credible scientific narrative—showing how enhanced local immune activation could complement checkpoint inhibition. We developed congress content to highlight early pharmacokinetic and pharmacodynamic data, created briefing materials for KOL discussions, and supported publications that contextualized the technology against existing modes of pembrolizumab delivery. Communications emphasized rigor, comparability, and regulatory alignment, ensuring oncology audiences viewed the platform as both innovative and credible.
Results
By reframing the device around its relevance to immuno-oncology, the company elevated visibility among oncology KOLs, strengthened confidence in the translational science, and positioned itself as a partner capable of extending the reach of checkpoint inhibitors through differentiated delivery.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.
Let's Partner
Generating the
Biology Century
We help life sciences teams cut through complexity and move from biology to belief—sharper, faster, leaner.